# | Title | Journal | Year | Citations |
---|
1 | The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) | Cancer | 2007 | 356 |
2 | Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors | Blood | 2016 | 246 |
3 | Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. | Journal of Clinical Oncology | 1991 | 242 |
4 | Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome | Leukemia | 1996 | 218 |
5 | Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect | Bone Marrow Transplantation | 1997 | 209 |
6 | Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. | Journal of Clinical Oncology | 1990 | 174 |
7 | Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups | Lancet, The | 1994 | 173 |
8 | Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase | Blood | 1995 | 164 |
9 | Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study | Leukemia | 1997 | 157 |
10 | Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis | Cancer | 2016 | 156 |
11 | Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. | Journal of Clinical Oncology | 1990 | 147 |
12 | Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition | Oncogene | 1997 | 146 |
13 | Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. | Journal of Clinical Oncology | 1991 | 125 |
14 | Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia | Leukemia | 1997 | 122 |
15 | Fludarabine therapy in Waldenström's macroglobulinemia | American Journal of Medicine | 1993 | 116 |
16 | Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases | Leukemia Research | 2015 | 115 |
17 | Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia | Leukemia | 1997 | 92 |
18 | Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation | Bone Marrow Transplantation | 1997 | 89 |
19 | Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. | Journal of Clinical Oncology | 1991 | 87 |
20 | The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia | Leukemia | 1997 | 84 |
21 | Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies | Gynecologic Oncology | 2013 | 77 |
22 | First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial | Lancet Haematology,the | 2014 | 77 |
23 | Allogeneic blood stem cell transplantation in advanced hematologic cancers | Bone Marrow Transplantation | 1997 | 76 |
24 | Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2 | Bone Marrow Transplantation | 1997 | 73 |
25 | Treatment of Therapy-Related Leukemia and Myelodysplastic Syndrome | Hematology/Oncology Clinics of North America | 1993 | 70 |
26 | Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases | Leukemia | 1997 | 69 |
27 | Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. | Journal of Clinical Oncology | 1990 | 64 |
28 | Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. | Journal of Clinical Oncology | 1992 | 60 |
29 | Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma | Blood | 2017 | 60 |
30 | Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16 | Leukemia | 1995 | 60 |
31 | Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults | Leukemia | 1996 | 60 |
32 | Bone marrow transplantation after failure of autologous transplant for non-Hodgkin’s lymphoma | Bone Marrow Transplantation | 1997 | 59 |
33 | High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. | Journal of Clinical Oncology | 1998 | 58 |
34 | Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit | Gene Therapy | 1995 | 56 |
35 | Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia | Leukemia | 1997 | 54 |
36 | Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment | Cell Death and Differentiation | 1998 | 54 |
37 | Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase | Blood | 1995 | 52 |
38 | Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia | Leukemia | 1995 | 51 |
39 | WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia | Leukemia | 1999 | 50 |
40 | Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement | Cancer | 2011 | 50 |
41 | Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia | Leukemia | 1998 | 47 |
42 | Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs? | Bone Marrow Transplantation | 2008 | 47 |
43 | Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia | Leukemia | 1995 | 47 |
44 | Peripheral Blood Progenitor Cell Transplantation: A Replacement for Marrow Auto‐ or Allografts | Stem Cells | 1996 | 45 |
45 | Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation | European Journal of Haematology | 2016 | 44 |
46 | All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia | Cancer | 1994 | 43 |
47 | GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia | Leukemia | 1998 | 43 |
48 | Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study | Bone Marrow Transplantation | 2001 | 42 |
49 | Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO) | Haematologica | 2017 | 40 |
50 | Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes | Leukemia | 1996 | 40 |